Abstract
Supplementary Figure S5 shows that there was no adverse uptake for TPP-45142 compared with TPP-45161 in different organs. Heart, liver, kidney and spleen accumulation of 89Zr-TPP-45142 or non-HER2 negative control 89Zr-TPP-45161 as measured by PET/CT imaging (n = 3) (time: post radiolabeled-compound injection).